Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study
Diagnostics · 16.05.2025 · 15 (10) · 1266
DOI: 10.3390/diagnostics15101266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.05.2025. Verfasst von Ismail Karluka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Adana Dr. Turgut Noyan Application and Research Center, Baskent University, Adana 01250, Turkey. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
This study aimed to evaluate the efficacy and safety of the Angio-Seal™ VIP vascular closure device (VCD) in achieving hemostasis following percutaneous transhepatic portal venous interventions.
Methods
This retrospective study evaluated 20 patients (mean age: 52.85 ± 16.18 years; 80% male) who underwent percutaneous transhepatic portal vein interventions followed by tract closure with the Angio-Seal™ device between January 2016 and September 2024. Procedural data, pre- and post-procedural hemoglobin and hematocrit levels, and complications were analyzed. Technical success was defined as the successful deployment of the device with immediate hemostasis and no evidence of bleeding on post-procedural imaging.
Results
Technical success, as defined in this study, was achieved in all 20 procedures (100%). The mean hemoglobin level declined from 11.91 ± 2.01 g/dL to 11.09 ± 2.19 g/dL (p < 0.001), and the mean hematocrit level decreased from 36.18 ± 6.03% to 32.98 ± 5.80% (p = 0.001). A hemoglobin drop ≥2 g/dL occurred in two patients (10%) and a hematocrit drop ≥4% in six patients (30%); none were associated with imaging or clinical evidence of hemorrhage. No major complications were observed. Minor complications, including localized pain managed with analgesics, occurred in five patients (25%). Follow-up imaging confirmed the absence of hemoperitoneum or device-related failure.
Conclusions
Angio-Seal™ is a technically feasible, safe, and effective option for tract closure following percutaneous transhepatic portal vein access. This single-device approach may offer a cost-effective alternative to traditional embolization techniques. However, more extensive prospective studies are required to validate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Radiology, Adana Dr. Turgut Noyan Application and Research Center, Baskent University, Adana 01250, Turkey.
ORCID-Profile: Ismail Karluka, Mustafa Mazıcan
Zitieren
APA
Karluka, I., & Mazıcan, M. (2025). Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study. Diagnostics, 15(10), 1266. https://doi.org/10.3390/diagnostics15101266
Vancouver
Karluka I, Mazıcan M. Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study. Diagnostics. 2025;15(10):1266. doi:10.3390/diagnostics15101266
BibTeX
@article{Karluka2025,
author = {Karluka, Ismail and Mazıcan, Mustafa},
title = {Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {10},
pages = {1266},
doi = {10.3390/diagnostics15101266}
}
EUVIMED